AngioDynamics Receives Expanded "No Chest X-Ray" FDA Clearance for Celerity Tip Location System


ALBANY, N.Y. – AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration (FDA) cleared an expanded indication for the Celerity tip location system.



The new clearance allows for the elimination of a follow-up X-ray when the Celerity system is used to aid in positioning Peripherally Inserted Central Catheters (PICCs) in adults. The system works by utilizing the patient's cardiac electrical activity to provide real time catheter tip location, offering accuracy on par with similar devices currently marketed, at or above 97% as compared to chest X-ray.1



"I am very pleased we achieved this essential milestone for our Vascular Access business" said Joseph M. DeVivo, AngioDynamics' President and Chief Executive Officer. "This new indication will provide more efficient use for patients and clinicians, and unlock the potential of BioFlo PICCs for customers who rely on a tip location device exclusively."



According to recent early data collected by Nurse Pro Plus, a third-party PICC placement contractor used by hospital systems throughout the U.S., the Celerity system is showing extremely favorable results for both patients and hospitals.



"Since we started using the Celerity tip location system, we have been seeing very successful results with our patients," said Nurse Pro Plus Owner Dan Estel. "As a service provider, we know that price plays a big factor, and the Celerity system matches well with BioFlo PICCs, which themselves are providing a favorable economic model for our business and the hospitals we serve. With our BioFlo PICC placements, we have seen decreased Alteplase use, as well as a reduction in DVTs."



"The cost savings associated with using the Celerity system to aid in PICC placements has created a strong demand from our clients," added Chuck Greiner, Senior Vice President of AngioDynamics' Vascular Access Business. "This expanded indication promises to reduce supply and labor cost for our customers, as well as optimize patient care by decreasing delays in treatment. Coupled with its ease of use with our thromboresistant BioFlo PICCs, the Celerity system will improve patient outcomes while reducing healthcare costs to many more hospitals and patients across the U.S."



1 Celerity Beta Site Experience, Nurse Pro Plus AVA Presentation on initial Celerity Experience, Sept. 3, 2014.



About AngioDynamics



AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com.



Trademarks

AngioDynamics, the AngioDynamics logo and BioFlo are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary. Celerity is trademarks and/or registered trademarks of Medical Components Inc.



CONTACT: Company Contact:

AngioDynamics Inc.

Mark Frost, CFO

(800) 772-6446 x1981

mfrost@AngioDynamics.com



Investor Relations Contacts:

EVC Group, Inc.

Chris Dailey/Robert Jones

(646) 445-4801; (646) 201-5447

cdailey@evcgroup.com; bjones@evcgroup.com



Media Contact:

EVC Group, Inc.

Dave Schemelia

(646) 201-5431

dave@evcgroup.com

All Topics